On Thursday, Boehringer Ingelheim announced it is reducing its workforce, eliminating positions in Connecticut.
In a statement, the company said it made the decision to cut 244 positions in July, which includes “120 in small molecule Discovery Research and 60 in other functions located in Connecticut.”
Officials said the company has reduced its sales force by an additional 64 positions nationwide.
“The actions we are taking now will help us reinvent the way we serve the needs of our patients, and enable us to continue to identify new medical breakthroughs,” the company said in a press release.
The press release continued to say that for the company to “continue to deliver on our research strategy, we must create a leaner global Discovery Research organization by consolidating small molecule discovery to two sites in Biberach, Germany and Vienna, Austria. This decision will result in the closure of the small molecule discovery functions in Ridgefield, CT and Milan, Italy.”
The company said a new group will be formed and based out of Ridgefield in 2017, focusing on cancer immunology discovery research.
The new group will result in about 35 new positions in Connecticut.
“We are sympathetic to the impact this decision will have on Boehringer Ingelheim employees and their families. We are committed to treating all employees with dignity, respect and sensitivity. We will support affected employees in a number of ways, including severance, outplacement services, and identifying other employment opportunities within the Boehringer Ingelheim network, as appropriate,” the press release said.
Copyright 2016 WFSB (Meredith Corporation). All rights reserved.